Open AccessCirculating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
Author(s) -
Tenna Vesterman Henriksen,
Noelia Tarazona,
Amanda Frydendahl,
Thomas Reinert,
Francisco Gimeno-Valiente,
Juan Antonio Carbonell-Asíns,
Shruti Sharma,
Derrick Renner,
Dina Hafez,
Desamparados Roda,
Marisol Huerta,
Susana Roselló,
Anders Husted Madsen,
Uffe S. Løve,
Per Vadgaard Andersen,
Ole Thorlacius-Ussing,
Lene Hjerrild Iversen,
Kåre Andersson Gotschalck,
Himanshu Sethi,
Alexey Aleshin,
Andrés Cervantes,
Claus L. Andersen
Publication year - 2021
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-21-2404
Subject(s) - medicine , colorectal cancer , confidence interval , stage (stratigraphy) , minimal residual disease , oncology , circulating tumor dna , gastroenterology , adjuvant therapy , multiplex , adjuvant , cancer , bioinformatics , paleontology , leukemia , biology
Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates.